8
當(dāng)前位置：北京百奧創(chuàng)新科技有限公司>>Gibco>> A4238501CTS™ Essential 6 Medium
CTS™ Essential 6 Medium
The formulation is based on a medium originally developed by Guokai Chen, et al., in the laboratory of James Thomson (1). With only six essential components, CTS Essential 6 Medium helps minimize variability. To complete your PSC workflow with a matching culture medium for the growth and expansion of PSCs, use CTS Essential 8 Medium.
CTS Essential 6 Medium:
• Provides a flexible format to suit different applications
• Facilitates regulatory filings through cGMP manufacturing and the availability of documentation
• Simplifies the transition from bench to clinic through the direct replacement of RUO Essential 6 Medium
Provides a flexible format:
CTS Essential 6 Medium does not contain bFGF or TGFβ and so can support the formation of embryoid bodies. This medium can support the directed differentiation of various cell types and somatic cell reprogramming using a variety of methods.
Facilitates regulatory filings:
CTS Essential 6 Medium is manufactured at a site that uses methods and controls that conform with cGMP for medical devices, 21 CFR Part 820. Our FDA-registered manufacturing site is ISO 13485-certified. Full documentation traceability and convenient access to our Drug Master File (DMF) are available for CTS Essential 6 Medium.
Simplifies transition from bench to clinic:
CTS Essential 6 Medium contains the same six essential components as RUO Essential 6 Medium, and with its cGMP manufacturing process, this fully-defined formulation helps minimize variability. Like RUO Essential 6 Medium, CTS Essential 6 Medium does not contain bFGF or TGF-beta, which inhibits differentiation and negatively affects reprogramming efficiency, respectively. With its additional safety testing, including adventitious agents, CTS Essential 6 Medium enables a smooth transition from RUO Essential 6 Medium.
